I-07 Hyun-moon Back A Mechanistic multicompartmental Pharmacokinetic model for food effect of fenofibrate Wednesday 10:45-12:15 |
I-08 Kathryn Ball Semi-physiological population pharmacokinetic modelling of renal transporter-mediated clinical drug-drug interactions Wednesday 10:45-12:15 |
I-09 Guillaume Baneyx Population PK model describing multiple peaks after a single oral administration of buparlisib in healthy volunteers. Wednesday 10:45-12:15 |
I-17 Marival Bermejo Level A IVIVC for Carbamazepine IR formulations and in vitro dissolution specifications using one-step approaches Wednesday 10:45-12:15 |
I-28 Jens Markus Borghardt A New Parameterisation to Describe Parallel Absorption Processes After Drug Inhalation Wednesday 10:45-12:15 |
I-50 Mohammed Cherkaoui Rbati Mechanistic Model to Predict DDIs in the Liver Wednesday 10:45-12:15 |
I-56 Eirini Christodoulou Pharmacokinetics of Crocus sativus L. aqueous extract after peros and intravenous administration to C57/BL6J mice Wednesday 10:45-12:15 |
I-62 Teresa Dalla Costa Population analysis of levofloxacin in plasma, lung and prostrate measured by microdialysis in Wistar rats after intravenous and intratracheal administration Wednesday 10:45-12:15 |
I-64 Adam Darwich Gastric emptying and its covariates Wednesday 10:45-12:15 |
I-68 Mailys De Sousa Mendes Prediction of human foetal pharmacokinetic profile using transplacental parameters from ex-vivo human placenta perfusion model and pregnancy-Physiologically Based Pharmacokinetic models Wednesday 10:45-12:15 |
I-69 Elien De Thaye Model-based comparison of modified-release metoprolol formulations in beagle dogs and rabbits Wednesday 10:45-12:15 |
II-02 Jan-Frederik Schlender Application of an elderly PBPK model to specify age-dependent changes of active processes Wednesday 15:15-16:40 |
II-16 Byungjeong Song Application of simplified-ACAT model for specific angiotensin receptor blocker in rats to human Wednesday 15:15-16:40 |
II-20 Marios Spanakis Application of Simcyp® simulator platform for the assessment of the pharmacokinetic profile of Gd-DOTA regarding its disposition in brain tumors lesions with different vasculature Wednesday 15:15-16:40 |
II-32 Donato Teutonico Development of a Cardio-Vascular Systems Pharmacology Platform Wednesday 15:15-16:40 |
II-35 Yingying Tian Physiologically based pharmacokinetic model incorporating genetic polymorphism of CYP2D6 to predict the nonlinear kinetics of paroxetine Wednesday 15:15-16:40 |
II-37 Huybrecht T'jollyn The effect of albumin redistribution on the PK of highly bound drugs: a simulation study using the Simcyp M&S platform Wednesday 15:15-16:40 |
II-40 Nikolaos Tsamandouras Application of the MCMC Bayesian estimation method in NONMEM in the context of physiologically-based pharmacokinetic modelling. Wednesday 15:15-16:40 |
II-52 Chris Walsh Use of a physiologically-based pharmacokinetic modelling and simulation approach to rationalise actinomycin D dosing in paediatric oncology Wednesday 15:15-16:40 |
II-55 Benjamin Weber New Insights in the Pulmonary Fate of Inhaled Drugs Wednesday 15:15-16:40 |
II-67 Christine Xu Application of physiologically based pharmacokinetic (PBPK) modeling for prediction of complex drug-drug interactions involving induction and inhibition of CYP3A4 by fedratinib Wednesday 15:15-16:40 |
II-75 Simon Zhou Complex absorption affecting terminal half-lives leading to pseudo “flip-flop” pharmacokinetics Wednesday 15:15-16:40 |
III-02 Irene-Ariadne Kechagia A simulation study to investigate the identifiability of parameters in a minimal PBPK model structure with target binding Thursday 10:20-11:45 |
III-12 Sylvain Fouliard Interpretability is coming: using a minimal PBPK model in a population analysis Thursday 10:20-11:45 |
III-17 Saskia Fuhrmann Effect of mouse model immunity on antibody biodistribution Thursday 10:20-11:45 |
III-26 Isabel Gonzalez-Alvarez Modelling of intestinal degradation and absorption of Clavulanic acid from In Vitro and In Situ data. Thursday 10:20-11:45 |
III-32 Benjamin Guiastrennec In vitro-in vivo modeling of erosion profiles for HPMC/DCP gel matrix tablets Thursday 10:20-11:45 |
III-44 Nick Holford The Influence of Body Composition on Ethanol Pharmacokinetics using a Rate Dependent Extraction Model Thursday 10:20-11:45 |
IV-04 Yan Li Characterization of the Oral Absorption Profiles of Sustained or Extended Release Formulations of Losartan, Dexibuprofen, Methylphenidate, and Tramadol Using Weibull Drug Release Functions Thursday 15:20-16:40 |
IV-08 Gaohua Lu Challenges in predicting the drug-drug interaction between dextromethorphan and rifampicin using a physiologically based pharmacokinetic (PBPK) model that includes three metabolites of dextromethorphan Thursday 15:20-16:40 |
IV-13 Victor Mangas-Sanjuan Population PK Model of Lithium and Drug Compliance Assessment Thursday 15:20-16:40 |
IV-14 Alison Margolskee You can’t always get what you want: The (mis)use of deconvolution in IVIVC Thursday 15:20-16:40 |
IV-28 Daniel Moj Is the ICRP reference man still suitable for physiologically-based pharmacokinetic (PBPK) modeling? Thursday 15:20-16:40 |
IV-31 Helen Musther Extended Validation of a Peripheral Sampling Site in PBPK modelling using Clarithromycin, Dextromethorphan, Dextrorphan, Erythromycin, Lidocaine and Tramadol Thursday 15:20-16:40 |
IV-39 Andrés Olivares-Morales A reduced physiologically-based pharmacokinetic (PBPK) model for the prediction of regional gastrointestinal (GI) drug absorption Thursday 15:20-16:40 |
IV-40 Edouard Ollier Clustering Absorption Profiles of Rivaroxaban Using Between Subject Model Mixture Thursday 15:20-16:40 |
IV-49 Eleni Pefani Drop-out estimation and PKPD analysis of a Phase 2a study for an anti-IL1R1 monoclonal antibody in Chronic Obstructive Pulmonary Disease (COPD) Thursday 15:20-16:40 |
IV-73 Muhammad Waqas Sadiq A whole-body physiologically based pharmacokinetic (WBPBPK) model of ciprofloxacin for prediction of bacterial killing at the site of infection Thursday 15:20-16:40 |